Biohaven Stock Surges 8.4% After Analyst Upgrade

The Goldman Sachs Group upgraded Biohaven to a strong-buy rating, sending the stock higher.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Shares of Biohaven Ltd. (NYSE:BHVN) jumped 8.4% on Monday after The Goldman Sachs Group upgraded the stock to a strong-buy rating. The stock traded as high as $12.61 before closing at $12.58, with approximately 878,595 shares changing hands during the session.

Why it matters

Biohaven is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases. The analyst upgrade suggests increased confidence in the company's pipeline and future prospects, which could be a positive sign for investors.

The details

Several analysts have weighed in on Biohaven recently. TD Cowen reaffirmed a 'buy' rating on the stock, while Morgan Stanley reduced its price target from $26 to $21 and Bank of America downgraded the stock from 'buy' to 'neutral'. However, the Goldman Sachs upgrade appears to have outweighed these other recent actions, driving the stock higher on Monday.

  • Biohaven's stock closed at $11.60 on the previous trading day.

The players

The Goldman Sachs Group

A multinational investment bank and financial services company that upgraded Biohaven's stock to a strong-buy rating.

Biohaven Ltd.

A clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases.

Got photos? Submit your photos here. ›

The takeaway

The analyst upgrade from Goldman Sachs is a positive sign for Biohaven, as it suggests increased confidence in the company's ability to develop successful therapies and grow its business. However, the stock's performance will ultimately depend on the company's continued progress in its clinical trials and regulatory approvals.